Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Telix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $3.26 billion
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 323.40 million
Earnings per share -0.149
Dividend per share N/A
Year To Date Return 32.32%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Telix Pharmaceuticals Ltd (ASX: TLX)
    Latest News

    A diverse group of people form a circle at a park and raise their arms together.
    Share Market News

    Here are the top 10 ASX 200 shares today

    It was a happy end to November for ASX investors this Thursday.

    Read more »

    A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
    Share Market News

    Here are the top 10 ASX 200 shares today

    The ASX 200 closed the trading week on a positive note today.

    Read more »

    A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
    Growth Shares

    Could buying these ASX shares at $9 now be like investing in Tesla in 2010?

    This Melbourne company is making big strides in its field and has returned a phenomenal 67% each year for its…

    Read more »

    A couple are happy sitting on their yacht.
    Investing Strategies

    Invest in these 2 ASX shares for a real shot at $1 million

    Getting to seven figures is possible, but only if you give it a try. Check out these stocks that could…

    Read more »

    A bored woman looking at her computer, it's bad news.
    Share Market News

    Here are the top 10 ASX 200 shares today

    Do you own any of today's top-best performing ASX 200 shares?

    Read more »

    Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    The ASX 200 slipped back into loss territory this Wednesday.

    Read more »

    Seven people look for bargains to buy at a yard sale.
    Cheap Shares

    7 oversold ASX shares to buy in November 2023

    With great market falls often come great buying opportunities...

    Read more »

    A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
    Share Fallers

    Telix Pharmaceuticals share price sinks 12% despite rocketing revenue

    Positive cash flows, growing revenue, improving cash balance. Why are investors still displeased?

    Read more »

    A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
    Share Fallers

    Why AMP, Netwealth, Pilbara Minerals, and Telix shares are dropping today

    These ASX shares are having a difficult session on Thursday.

    Read more »

    A woman looks in anticipation at her laptop, watching eagerly.
    Share Market News

    5 things to watch on the ASX 200 on Thursday

    It looks set to be a very red day for the ASX 200 index on Thursday.

    Read more »

    Middle age caucasian man smiling confident drinking coffee at home.
    Investing Strategies

    ASX passive income of $200 a week? See how you can do it for $5 per day

    For the price of a cup of coffee each morning, you could be raking in money for doing nothing for…

    Read more »

    a bearded man sits at his desk with hands behind his head and feet on his desk smiling widely while looking at his computer screen which has market data on it, indicating a please share price rise.
    Growth Shares

    20% a year? 3 ASX growth shares that doubled in 4 years

    Here are some examples of how ordinary punters can hit the jackpot through diligent research.

    Read more »

    Frequently Asked Questions

    No, Telix does not pay dividends at this time. 

    Telix Pharmaceuticals Ltd listed on the ASX on 15 November 2017.

    TLX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Telix Pharmaceuticals Ltd

    Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.

    Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe. 

    The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States. 

    TLX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    30 Nov 2023 $10.08 $0.41 4.24% 1,557,023 $9.84 $10.12 $9.76
    29 Nov 2023 $9.67 $0.05 0.52% 476,116 $9.72 $9.72 $9.46
    28 Nov 2023 $9.62 $0.22 2.34% 415,702 $9.31 $9.65 $9.31
    27 Nov 2023 $9.40 $0.03 0.32% 1,589,339 $9.41 $9.45 $9.33
    24 Nov 2023 $9.37 $0.19 2.07% 249,088 $9.25 $9.41 $9.20
    23 Nov 2023 $9.18 $0.04 0.44% 524,349 $9.14 $9.41 $9.12
    22 Nov 2023 $9.14 $-0.22 -2.35% 528,072 $9.38 $9.39 $9.09
    21 Nov 2023 $9.36 $0.23 2.52% 761,558 $9.31 $9.47 $9.20
    20 Nov 2023 $9.13 $-0.26 -2.77% 1,057,112 $9.56 $9.60 $9.03
    17 Nov 2023 $9.39 $0.38 4.22% 852,023 $9.20 $9.55 $9.15
    16 Nov 2023 $9.01 $-0.22 -2.38% 721,313 $9.26 $9.26 $8.94
    15 Nov 2023 $9.23 $-0.05 -0.54% 469,444 $9.40 $9.51 $9.21
    14 Nov 2023 $9.28 $0.13 1.42% 411,210 $9.40 $9.43 $9.22
    13 Nov 2023 $9.15 $-0.30 -3.17% 657,093 $9.50 $9.56 $9.15
    10 Nov 2023 $9.45 $-0.12 -1.25% 536,771 $9.45 $9.58 $9.38
    09 Nov 2023 $9.57 $0.02 0.21% 618,259 $9.65 $9.79 $9.49
    08 Nov 2023 $9.55 $0.16 1.70% 805,745 $9.60 $9.62 $9.43
    07 Nov 2023 $9.39 $0.15 1.62% 436,563 $9.25 $9.41 $9.20
    06 Nov 2023 $9.24 $0.00 0.00% 850,876 $9.30 $9.43 $9.21
    03 Nov 2023 $9.24 $0.14 1.54% 857,962 $9.24 $9.45 $9.18
    02 Nov 2023 $9.10 $0.12 1.34% 490,429 $9.14 $9.21 $9.03
    01 Nov 2023 $8.98 $0.14 1.58% 857,911 $8.99 $9.12 $8.93

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    30 May 2023 Christian Behrenbruch Issued 120,268 $356,738
    Director remuneration. Black Scholes valuation, 2,59,940 rIGHTS
    16 Mar 2023 Tiffany Olson Buy 51,305 $343,385
    On-market trade. average price
    12 Dec 2022 Tiffany Olson Buy 10,930 $73,255
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Harry Kevin McCann Non-Executive ChairmanNon-Executive Director Sep 2017
    Mr McCann has board experience with some of Australia's recognised companies. Kevin is a former corporate lawyer and experienced Chairman and Director of listed private and government companies and government agencies. Previously, Kevin has been Chairman of Macquarie Group and Macquarie Bank Limited, Chairman of Origin Energy Limited, Healthscope Limited, the Sydney Harbour Federation Trust and a Director of Bluescope Steel. He is Chair of People, Culture and Disclosure Committee and member of Risk Committee.
    Ms Jann E Skinner Non-Executive Director Jun 2018
    Ms Skinner has experience in audit and accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004. Jann is an independent Non-Executive Director of QBE Insurance Group Limited, where she also serves as Chair of the Audit Committee and Deputy Chair of the Risk and Capital Committee. She also serves as a Director of the Create Foundation Limited and HSBC Bank Australia Limited. He is the Chair of Risk Committee and member of People, Culture and Disclosure Committee (for financial related disclosures).
    Dr Christian Peter Behrenbruch Chief Executive OfficerManaging Director Jan 2017
    Dr Behrenbruch has over twenty years of healthcare entrepreneurship and executive leadership experience. He has previously served in a CEO or Executive Director capacity at Mirada Solutions, CTI Molecular Imaging (now Siemens Healthcare), Fibron Technologies and ImaginAb, Inc. He is a former Director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (Adaptix) and was the former Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre). He is a member of Disclosure Committee.
    Dr Andreas Kluge Non-Executive Director Jan 2017
    Dr Kluge has over 20 years of clinical research and development experience, including as Founder, General Manager and Medical Director for ABX-CRO, a full service CRO for Phase I-III biological, radiopharmaceutical, and anticancer trials based in Dresden, Germany. He is also Founder and was founding CEO of ABX GmbH (, one of the manufacturers of radiopharmaceutical precursors globally. Andreas is further Founder, General Manager and Medical Director for Therapeia, an early-stage development company in the field of neurooncology, which was acquired by Telix. Andreas has experience in the practice of Nuclear Medicine and radiochemistry, molecular imaging and the clinical development of novel radionuclide-based products and devices.
    Dr Mark Alexander Nelson Non-Executive Director Sep 2017
    Dr Nelson is Chairman and Co-Founder of the Caledonia Investments Group, and a Director of The Caledonia Foundation. Previously Mark was a Director of The Howard Florey Institute of Experimental Physiology and Medicine and served on the Commercialisation Committee of the Florey Institute. He is a member of Risk, People and Culture Committee.
    Ms Tiffany Olson Non-Executive Director Mar 2022
    Ms Olson brings experience in commercialisation and corporate strategy in oncology, including in the radiopharmaceutical sector. Her most recent executive role was with Cardinal Health, the provider of radiopharmaceuticals in the United States, where she was President of Cardinal Health Nuclear and Precision Health Solutions overseeing Cardinal's radiopharmaceutical manufacturing and nuclear pharmacy network. During her eight-year tenure in this role she led a major business transformation which led to increased market share and profit growth. Prior to her role at Cardinal Health, Ms. Olson served as President of NaviMed and in executive roles at Eli Lilly and Roche, where she attained the position of President and CEO of Roche Diagnostics Corporation. She is a member of Risk Committee.
    Ms Genevieve Ryan Company Secretary Dec 2022
    Genevieve Ryan Company Secretary
    Richard Valeix Group Chief Commercial Officer
    Darren Smith Group Chief Financial Officer
    Colin Hayward Group Chief Medical Officer

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 40,150,674 12.68%
    Citicorp Nominees Pty Limited 31,011,771 9.79%
    J P Morgan Nominees Australia Pty Limited 27,441,529 8.66%
    Elk River Holdings Pty Ltd As Trustee For The Behrenbruch Family Trust And C Behrenbruch 22,675,000 7.16%
    Gnosis Verwaltungsgesellschaftm B H 22,675,000 7.16%
    National Nominees Limited 12,886,518 4.07%
    Grand Decade Developments Limited 10,947,181 3.46%
    Uv Cap Gmbh and Co Kg 7,525,000 2.38%
    BNP Paribas Nominees Pty Ltd 6,675,428 2.11%
    The Oncidium Foundation 6,239,360 1.97%
    BNP Paribas Noms Pty Ltd 5,443,420 1.72%
    Scintec Diagnostics Gmbh 4,312,151 1.36%
    Hsbc Custody Nominees (Australia) Limited A/C 2 3,673,399 1.16%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 3,264,410 1.03%
    Man Holdings Pty Ltd 3,228,750 1.02%
    Pacific Custodians Pty Limited 2,399,466 0.76%
    Yelwac Pty Ltd 2,381,804 0.75%
    UBS Nominees Pty Ltd 2,070,025 0.65%
    Netwealth Investments Limited 1,955,439 0.62%
    Jean-Francois Chatal 1,797,069 0.57%
    Warbont Nominees Pty Ltd 1,753,946 0.55%